Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, t…
$40.31+0.02%
报价 2026-11-06
市值
$177.74B
EV
–
PE (TTM)
10.3x
预期 PE
–
52 周区间距高点 -37.0%
$35.29$63.98
筛选结果
pipeline · 2026-11-06Keep✗ 高增长✓ Cheap✗ GARP
Cheap Pool: PE <= 12, EV/EBITDA <= 8
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Drug Manufacturers - General| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| NVONovo Nordisk A/S | $177.74B | +0.0% | – | 78.2% | 10.3x | 7.2x | – | Cheap |
| NVSNovartis AG | $307B | +0.4% | – | 76% | 20.2x | 13.5x | – | |
| AZNAstraZeneca PLC | $289.13B | -0.2% | – | 78.2% | 27.5x | 15.4x | – | |
| AMGNAmgen Inc. | $248.92B | +0.0% | +4.0% | 70.5% | 24.4x | 12.5x | 30.7x | |
| GILDGilead Sciences, Inc. | $207B | -0.4% | +4.1% | 81.1% | 20.0x | 14.5x | 21.9x | |
| PFEPfizer Inc. | $167.51B | -0.2% | +1.4% | 72.8% | 37.3x | 17.7x | 14.7x | |
| BMYBristol-Myers Squibb Company PFD CONV 2 | $127.02B | -1.6% | -1.5% | 67.7% | 16.5x | 10.5x | 9.9x | |
| SNYSanofi | $113.26B | +0.3% | – | 71.7% | 8.9x | 9.7x | – | |
| GSKGSK plc | $102.02B | -0.2% | – | 72.5% | 13.7x | 7.8x | – | |
| 同行中位数 | – | – | +2.7% | 72.6% | 20.1x | 13.0x | 18.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
报告货币 DKK（非美元）| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | DKK 78.49B | DKK 96.82B | DKK 79.14B | DKK 74.98B | DKK 76.86B | DKK 78.09B | DKK 85.68B | DKK 71.31B |
| Gross Margin | 78.2% | 86% | 80.9% | 76.1% | 83.3% | 83.5% | 84.8% | 84.1% |
| Operating Margin | 34.5% | 61.6% | 40.1% | 31.6% | 43.5% | 49.7% | 42.9% | 47.4% |
| Net Income | DKK 20.99B | DKK 48.56B | DKK 26.89B | DKK 20.01B | DKK 26.5B | DKK 29.03B | DKK 28.23B | DKK 27.3B |
| Diluted EPS | 4.74 | 10.91 | 6.04 | 4.5 | 5.96 | 6.53 | 6.33 | 6.12 |
| Operating Cash Flow | DKK 55.2B | DKK 24.08B | DKK 7.62B | DKK 46.11B | DKK 40.79B | DKK 24.59B | DKK 12.3B | DKK 43.85B |
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。